Article
Oncology
Mingdi Zhang, Kejin Wu, Peng Zhang, Maoli Wang, Fang Bai, Hongliang Chen
Summary: BCS shows independent favorable prognostic factor and can be acceptable and preferable alternative to mastectomy for well-selected early-stage T1 or T2 CLBC patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Quyen D. Chu, Mei-Chin Hsieh, Yong Yi, John M. Lyons, Xiao-Cheng Wu
Summary: A study was conducted to evaluate the outcomes of breast-conserving therapy (BCT) and mastectomy (MST) for women with early-stage breast cancer (ESBC). The results showed that BCT yielded better survival rates than MST for all subtypes of ESBC. The role of mastectomy in the treatment of ESBC should be reassessed in future clinical trials.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2022)
Article
Multidisciplinary Sciences
Han Shin Lee, Hee Jeong Kim, Il Yong Chung, Jisun Kim, Sae Byul Lee, Jong Won Lee, Byung Ho Son, Sei Hyun Ahn, Hak Hee Kim, Joon Beom Seo, Jin Hee Ahn, Gyungyub Gong, Sangwook Lee, Namkug Kim, Beom Seok Ko
Summary: The study demonstrated the use of 3D printed-breast surgical guides for breast cancer patients undergoing neoadjuvant systemic therapy, which proved to be effective in identifying and marking the original tumor area during breast-conserving surgery.
SCIENTIFIC REPORTS
(2021)
Article
Surgery
Chu-Ying Chen, Ya-Chen
Summary: By analyzing long-term follow-up data of MPTB patients, it was found that breast-conserving surgery (BCS) has a better survival rate compared to mastectomy. Therefore, BCS should be prioritized in MPTB patients when both surgical approaches are feasible.
UPDATES IN SURGERY
(2023)
Article
Oncology
Changjun Wang, Yan Lin, Hanjiang Zhu, Yidong Zhou, Feng Mao, Xin Huang, Xingtong Zhou, Xi Cao, Qiang Sun
Summary: This meta-analysis found that breast-conserving therapy (BCT) carries an increased risk of local recurrence but does not significantly impact patient survival in terms of disease-free survival, metastasis-free survival, breast cancer-specific survival, and overall survival.
Review
Oncology
Caiqin Mo, Weihong Ruan, Junyu Lin, Huaying Chen, Xiangjin Chen
Summary: Repeat breast-conserving surgery (RBCS) has a higher secondary local recurrence rate compared to salvage mastectomy (SM) for patients with ipsilateral breast tumour recurrence (IBTR), but it does not significantly affect survival rates. RBCS may be considered as an alternative method for IBTR patients after breast-conserving surgery (BCS).
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Gang Liu, Xiangyi Kong, Qichen Dai, Han Cheng, Jing Wang, Jidong Gao, Yipeng Wang
Summary: This article reports on the clinical characteristics and prognosis of Chinese breast cancer patients, evaluating their overall survival and disease-free survival. The study highlights the importance of personalized treatment strategies and emphasizes the advantages of breast-conserving surgery.
Article
Oncology
Ivica Ratosa, Gaber Plavc, Nina Pislar, Tina Zagar, Andraz Perhavec, Pierfrancesco Franco
Summary: This study compared survival outcomes in 1360 patients with early-stage breast cancer, showing that patients treated with breast-conserving therapy had lower rates of recurrence and equivalent overall survival compared to those treated with mastectomy alone. The findings emphasize the importance of adjuvant treatments, including radiation therapy, in improving disease-specific outcomes for early-stage breast cancer patients.
Article
Oncology
Jin Wang, Hailin Tang, Kanhua Yin, Xing Li, Xiaoming Xie, Kevin S. Hughes
Summary: After breast-conserving therapy, patients may experience ipsilateral breast tumor recurrence, new primary tumor, or contralateral breast cancer. Patients with true recurrence have poorer survival outcomes compared to those with new primary tumors, while the survival outcomes of contralateral breast cancer are better.
Article
Medicine, General & Internal
Zhi-Hong Sun, Chuang Chen, Xin-Wen Kuang, Jun-Long Song, Sheng-Rong Sun, Wei-Xing Wang
Summary: This study found that, compared to mastectomy, breast-conserving therapy (BCT) can provide better breast cancer-specific survival and overall survival benefits in young white patients under 40 with early-stage breast cancer, especially in the 36 to 40 years age group.
Article
Oncology
Gabriela Bezerra Nobrega, Bruna Salani Mota, Gabriela Boufelli de Freitas, Jonathan Yugo Maesaka, Rosa Maria Salani Mota, Rodrigo Goncalves, Angela Francisca Trinconi, Marcos Desiderio Ricci, Jose Roberto Piato, Jose Maria Soares-Jr, Edmund Chada Baracat, Jose Roberto Filassi
Summary: BCS is associated with superior OS rates compared to MS in patients with LABC following NAT. Lower BMI, lower pretreatment stage, and achieving PCR were associated with improved survival outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Surgery
Ye-Wei Yuan, Peng-Cheng Liu, Fang-Fang Li, Ya-Han Yang, Wei Yang, Li Fan, De-Wu Mou, Hong-Wei Yang, Mao-Shan Chen
Summary: This study found that breast-conserving therapy (BCT) is an acceptable and preferable alternative to mastectomy for patients with centrally located breast cancer (CLBC).
Article
Oncology
Shengyu Pu, Shaoran Song, Heyan Chen, Can Zhou, Huimin Zhang, Ke Wang, Jianjun He, Jian Zhang
Summary: Breast-conserving surgery (BCS) may bring better overall survival and breast cancer-specific survival for young breast cancer patients. A model was constructed to identify appropriate candidates who benefit from BCS.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Song Wang, Yiyuan Zhang, Fangxu Yin, Xiaohong Wang, Zhenlin Yang
Summary: In women with early-stage IMPC, breast-conserving treatment was found to be at least equivalent to mastectomy in terms of survival outcomes. BCT should be recommended as the standard surgical treatment, especially for patients with T2 disease, when both procedures are feasible.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Dang Van Nguyen, Sang-Won Kim, Young-Taek Oh, O. Kyu Noh, Yongsik Jung, Mison Chun, Dae Sung Yoon
Summary: Young women undergoing breast conserving therapy have a higher risk of local recurrence compared to mastectomy alone. Despite aggressive salvage treatments, those with local recurrence after breast conserving therapy have poor prognosis. Novel systemic treatments are needed to improve outcomes for young women with breast cancer undergoing breast conserving therapy.
Article
Oncology
X. He, F. J. Esteva, J. Ensor, G. N. Hortobagyi, M. -H. Lee, S. -C. J. Yeung
ANNALS OF ONCOLOGY
(2012)
Article
Oncology
X. -X. He, S. M. Tu, M. -H. Lee, S. -C. J. Yeung
ANNALS OF ONCOLOGY
(2011)
Article
Pharmacology & Pharmacy
Xuexin He, Su Li, He Huang, Zhiming Li, Likun Chen, Sheng Ye, Jiajia Huang, Jing Zhan, Tongyu Lin
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2011)
Article
Oncology
Xuexin He, Jiali Ji, Rongrong Dong, Hong Liu, Xiaolan Dai, Chongjian Wang, Francisco J. Esteva, Sai-Ching Jim Yeung
BREAST CANCER RESEARCH AND TREATMENT
(2019)
Article
Oncology
Xuexin He, Jiali Ji, Mei Tian, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching Jim Yeung
CLINICAL CANCER RESEARCH
(2019)
Review
Radiology, Nuclear Medicine & Medical Imaging
Mei Tian, Xuexin He, Chentao Jin, Xiao He, Shuang Wu, Rui Zhou, Xiaohui Zhang, Kai Zhang, Weizhong Gu, Jing Wang, Hong Zhang
Summary: Pathology is a medical specialty focused on studying the nature and causes of disease, and plays a crucial role in connecting basic research and clinical medicine. Challenges such as invasiveness and sample representativeness limitations exist in traditional pathology, while molecular imaging provides a noninvasive way to visualize and measure biological processes at the molecular level. A new pathophysiology visualization system based on molecular imaging is showing great potential in reforming pathological practice, driving improvements in trans-scale imaging, transparency, and translation processes.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Xuexin He, Jiali Ji, Xiaolan Dai, Aiham Z. Qdaisat, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching J. Yeung
Summary: This study reviewed early HER2-positive breast cancer patients at the institution from 1998 to 2009 and found that hypertension and history of coronary artery disease were independent prognostic factors for late severe CV events. Combining anthracycline and anti-HER2 therapy regimens was beneficial for improving overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Xuexin He, Xiaolan Dai, Jiali Ji, Hong Liu, Ganggang Shi, Sai-Ching Jim Yeung
Summary: This study compared the efficacy and cardiac toxicity of different neoadjuvant chemotherapy regimens in HER2+ breast cancer patients. The results showed that the PH-FECH regimen had higher progression-free survival and pathologic complete response rates compared to the TCH regimen, but it was associated with a higher risk of cardiac toxicity.
CLINICAL BREAST CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaohui Zhang, Lin Chen, Han Jiang, Xuexin He, Liu Feng, Miaoqi Ni, Mindi Ma, Jing Wang, Teng Zhang, Shuang Wu, Rui Zhou, Chentao Jin, Kai Zhang, Wenbin Qian, Zexin Chen, Cheng Zhuo, Hong Zhang, Mei Tian
Summary: The hybrid nomograms combining RS with IPI significantly improved survival prediction in DLBCL. Radiomic analysis on MBV may serve as a potential approach for prognosis assessment in DLBCL.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Immunology
Qing Zhao, Xuexin He, Xiyi Qin, Yu Liu, Han Jiang, Jing Wang, Shuang Wu, Rui Zhou, Congcong Yu, Suling Liu, Hong Zhang, Mei Tian
Summary: This study explores a novel combination therapy for TNBC using Losartan and Dox-L in combination with alpha-PD1, demonstrating that it can optimize the efficacy by reducing the stroma and enhancing immune stimulation, which improves the immunosuppressive microenvironment and enhances anti-tumor immunity.
FRONTIERS IN IMMUNOLOGY
(2022)